首页> 外文期刊>Hepato-gastroenterology. >Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate.
【24h】

Transcatheter arterial chemoembolization therapy combined with percutaneous ethanol injection for unresectable large hepatocellular carcinoma: an evaluation of the local therapeutic effect and survival rate.

机译:经导管动脉化学栓塞治疗联合经皮乙醇注射治疗无法切除的大肝细胞癌:局部治疗效果和生存率的评估。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND/AIMS: This study was undertaken to evaluate the effectiveness of combination therapy with transcatheter arterial chemoembolization followed by percutaneous ethanol injection in patients with unresectable large hepatocellular carcinoma by comparing the use of this combined regimen with transcatheter arterial chemoembolization alone. METHODOLOGY: Six hundred and thirty-one consecutive patients with hepatocellular carcinoma lesions observed from Jan 1989 to Dec 1999 (11 years) at the Internal Medicine Department, Saga Prefectural Hospital Koseikan were retrospectively enrolled in the study. The series included 120 patients with large unresectable hepatocellular carcinoma lesions, the largest of which were greater than 3 cm in largest dimension. Fifty-two patients underwent a single transcatheter arterial chemoembolization followed by percutaneous ethanol injection, which were compared with 68 patients treated by transcatheter arterial chemoembolization alone. Both groups of patients with hepatocellular carcinoma did not differ regarding the base-line characteristics. The overall survival rates and recurrence ratio of initially treated lesions were compared in both groups. RESULTS: On overall survival rates by the Kaplan-Meier method, three- and five-year survival in the transcatheter arterial chemoembolization and percutaneous ethanol injection group (59.0%, 32.1%) proved to be significantly longer than those in the transcatheter arterial chemoembolization group (27.1%, 17.0%). In addition, during the follow-up local recurrence in the combination group (23.1%) was significantly lower than that in the transcatheter arterial chemoembolization group (50.0%). CONCLUSIONS: The combined treatment with transcatheter arterial chemoembolization and percutaneous ethanol injection proved to be more effective and safer. Furthermore, a lower incidence of local recurrence was observed than transcatheter arterial chemoembolization alone which resulted in an increased survival of the patients associated with unresectable large hepatocellular carcinoma lesions.
机译:背景/目的:通过比较将这种联合治疗方案与单独经导管动脉化疗栓塞术的使用进行比较,以评估经导管动脉化疗栓塞术联合经皮乙醇注射治疗不可切除的大肝细胞癌的疗效。方法:回顾性研究了自1989年1月至1999年12月(11年)在佐贺县立医院小清馆内科观察的631例肝细胞癌病变患者。该系列包括120例无法切除的肝细胞癌大病灶,其中最大的病灶最大尺寸大于3 cm。 52例患者接受了单次经导管动脉化疗栓塞,然后经皮乙醇注射,与68例单独经导管动脉化疗栓塞治疗的患者进行了比较。两组肝细胞癌患者的基线特征无差异。比较两组初始治疗病变的总生存率和复发率。结果:就Kaplan-Meier方法的总生存率而言,经导管动脉化疗栓塞和经皮乙醇注射组的3年和5年生存率(59.0%,32.1%)被证明比经导管动脉化学栓塞组明显更长。 (27.1%,17.0%)。此外,在随访期间,联合组的局部复发率(23.1%)显着低于经导管动脉化疗栓塞组(50.0%)。结论:经导管动脉化疗栓塞和经皮乙醇注射液联合治疗被证明更有效,更安全。此外,观察到局部复发的发生率比单独经导管动脉化疗栓塞的发生率低,这导致与无法切除的大肝细胞癌病变相关的患者存活率提高。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号